Conexeu Sciences Inc.(CNXU)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CNXU Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Conexeu Sciences Inc. (CNXU), a Healthcare sector company. CNXU is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. CNXU trades on the Nasdaq exchange and files with the SEC under CIK 2066836. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNXU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Conexeu Sciences Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-2.3M
ROIC
Q2 2026
-33.1%
AI Insight: CNXU Financial Trends
Single-quarter snapshot shows Conexeu burning cash with negative operating income and minimal equity cushion.
• Operating income negative at $-4M in Q2 2026; operating cash flow also negative at $-3M.
• Equity base of $7M is thin relative to net loss of $-4M in the quarter.
⚠ Insufficient data to assess revenue trend, margin trajectory, or leverage ratio — only one quarter available.
⚠ Cash burn rate and path to profitability unclear; runway relative to $7M equity needs clarification.
AI Insight: CNXU Ratio Trends
Insufficient data: CNXU reports no financial metrics for Q2 2026; unable to assess operational or capital efficiency trends.
⚠ Complete absence of reported ratios (OpMargin, NPM, ROE, ROA, ROIC, D/E) for Q2 2026 suggests missing financials or reporting delay.
Get alerted when CNXU's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Conexeu Sciences Inc. including:
More Healthcare Companies
View all Healthcare →Put CNXU on your watchlist
Track score changes the day Conexeu Sciences Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CNXU a good stock to buy?
13F Pro's AI-powered analysis of Conexeu Sciences Inc. (CNXU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CNXU are available on the CNXU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own CNXU?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CNXU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Conexeu Sciences Inc.'s investment landscape.